ANTINEOPLASTIC AGENTS
Browse ingredients, then choose a strength and product. Ontario inventory only; not a treatment recommendation.
DASATINIB: products 1 to 20 of 33.
Prices below are the ministry's recorded amounts per source unit, not pharmacy quotes or the patient's payment. Different strengths, forms and package units are not directly comparable. The cost plan asks for quantity and refill details.
| Product / strength / form | Ontario listing | Recorded ministry price | Next step |
|---|---|---|---|
| Apo-Dasatinib 100mg TabDIN 02470721 | Off-Formulary Interchangeable, not an ODB benefit | $132.2671per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib 20mg TabDIN 02470705 | Off-Formulary Interchangeable, not an ODB benefit | $32.8823per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib 50mg TabDIN 02470713 | Off-Formulary Interchangeable, not an ODB benefit | $66.1782per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib 70mg TabDIN 02481499 | Off-Formulary Interchangeable, not an ODB benefit | $72.9336per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib 80mg TabDIN 02481502 | Off-Formulary Interchangeable, not an ODB benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib Tablets 100mg TabDIN 02562502 | Off-Formulary Interchangeable, not an ODB benefit | $132.2671per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib Tablets 20mg TabDIN 02562464 | Off-Formulary Interchangeable, not an ODB benefit | $32.8823per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib Tablets 50mg TabDIN 02562472 | Off-Formulary Interchangeable, not an ODB benefit | $66.1782per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib Tablets 70mg TabDIN 02562480 | Off-Formulary Interchangeable, not an ODB benefit | $72.9336per source unit | Requirements & sourcesBuild cost plan |
| Apo-Dasatinib Tablets 80mg TabDIN 02562499 | Off-Formulary Interchangeable, not an ODB benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 100mg TabDIN 02514788 | Off-Formulary Interchangeable, not an ODB benefit | $132.2670per source unit | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 140mg TabDIN 02514796 | Off-Formulary Interchangeable, not an ODB benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 20mg TabDIN 02514737 | Off-Formulary Interchangeable, not an ODB benefit | $32.8823per source unit | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 50mg TabDIN 02514745 | Off-Formulary Interchangeable, not an ODB benefit | $66.1782per source unit | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 70mg TabDIN 02514753 | Off-Formulary Interchangeable, not an ODB benefit | $72.9336per source unit | Requirements & sourcesBuild cost plan |
| Reddy-Dasatinib 80mg TabDIN 02514761 | Off-Formulary Interchangeable, not an ODB benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Sprycel 100mg TabDIN 02320193 | Off-Formulary Interchangeable, not an ODB benefit | $132.2671per source unit | Requirements & sourcesBuild cost plan |
| Sprycel 140mg TabDIN 02360829 | Off-Formulary Interchangeable, not an ODB benefit | No price in this record | Requirements & sourcesBuild cost plan |
| Sprycel 20mg TabDIN 02293129 | Off-Formulary Interchangeable, not an ODB benefit | $32.8823per source unit | Requirements & sourcesBuild cost plan |
| Sprycel 50mg TabDIN 02293137 | Off-Formulary Interchangeable, not an ODB benefit | $66.1783per source unit | Requirements & sourcesBuild cost plan |
Not seeing a product? Search Canadian records by medication name or DIN. Absence from this Ontario extract does not establish non-coverage. Open an exact product for its dated Health Canada status; a listing is not a stock check.
Class sources and program rules
Ontario Ministry of Health: odb-formulary-ed43-extract-2026-08-26.xml, extract 2026-08-26. Ontario class index: formulary-ed43-front-matter.txt, Part V.
10:00 ANTINEOPLASTIC AGENTS.